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ABSTRACT
Introduction: Primary biliary cirrhosis (PBC) is an
autoimmune liver disease with approximately 50% of
patients experiencing fatigue. This can be a particularly
debilitating symptom, affecting quality of life and
resulting in social isolation. Fatigue is highlighted by
patients as a priority for research and patient support
groups were involved in designing this trial. This is the
first randomised controlled trial to investigate a
treatment for fatigue in PBC. The trial protocol is
innovative as it utilises novel magnetic resonance
spectroscopy (MRS) techniques as an outcome
measure. The protocol will be valuable to research
groups planning clinical trials targeting fatigue in PBC
and also transferrable to other conditions associated
with fatigue.
Methods and analysis: RITPBC is a Medical
Research Council (MRC) and National Institute for
Health Research (NIHR) Efficacy and Mechanism
Evaluation Programme (EME)-funded project. It is a
phase II, single-centre, randomised controlled, double-
blinded trial comparing rituximab with placebo in
fatigued PBC patients. 78 patients with PBC and
moderate to severe fatigue will be randomised to
receive two infusions of rituximab or placebo. The
study aims to assess whether rituximab improves
fatigue in patients with PBC, the safety, and tolerability
of rituximab in PBC and the sustainability of any
beneficial actions. The primary outcome will be an
improvement in fatigue domain score of the PBC-40, a
disease-specific quality of life measure, evaluated at
12-week assessment. Secondary outcome measures
include novel MRS techniques assessing muscle
bioenergetic function, physical activity, anaerobic
threshold and symptom, and quality of life measures.
The trial started recruiting in October 2012 and
recruitment is ongoing.
Ethics and dissemination: The trial has ethical
approval from the NRES Committee North East, has
Clinical Trial Authorisation from MHRA and local R&D
approval. Trial results will be communicated to
participants, presented at national and international
meetings and published in peer-reviewed journals.
Trial registration number: ISRCTN03978701.
BACKGROUND
Primary biliary cirrhosis (PBC) is a chronic
cholestatic liver disease with a prevalence of
30/100 000.1 It affects approximately 20 000
people in the UK, predominantly females
(10:1).2 PBC has an autoimmune aetiology
with the majority of patients expressing auto-
antibodies directed against mitochondrial and
nuclear antigens,3 and has strong associations
with other autoimmune diseases4 PBC is char-
acterised by inflammation and subsequent loss
of the small intrahepatic bile ducts. Despite its
name only a small number of patients will pro-
gress to cirrhosis and end-stage liver disease
and a number of these will require liver trans-
plantation.5 There is only one licensed treat-
ment, ursodeoxycholic acid (UDCA), which
slows progression of liver disease.6
Strengths and limitations of this study
▪ RITPBC is the first randomised controlled trial of
a treatment for fatigue in patients with primary
biliary cirrhosis (PBC).
▪ The trial describes novel mechanistic outcome
measures using magnetic resonance spectros-
copy (MRS).
▪ Novel recruitment strategies utilising the UK-PBC
trials platform are described.
▪ The main limitation is the responsivity of the
primary outcome measure to meaningful
improvement in fatigue. Responsivity is one of
the 6 psychometric properties of any measure
and determines its ability to measure meaningful
change in a symptom in response to effective
therapy. It is the untested one for the PBC-40
fatigue domain for the obvious reason that there
is no therapy able to improve fatigue to allow us
to test it. We have mitigated against this by
having an objective measure as well (activity)
and biomarkers (MRS).
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PBC is associated with a number of symptoms includ-
ing fatigue, cognitive impairment and pruritus. There
are treatments available for PBC-associated pruritus but
at present there are no licensed treatments for fatigue
or cognitive dysfunction. Fatigue, which patients
describe as physical exhaustion or their ‘batteries
running down’, can be a very debilitating symptom.
Fatigued patients are often unable to carry out normal
day-to-day activities and frequently are unable to work
resulting in a negative impact on quality of life.7 Recent
data suggests that when patients have social isolation in
combination with fatigue, there is a negative impact on
quality of life.8 One patient with PBC has very eloquently
described the impact of fatigue from PBC and the lone-
liness, frustration and despair that can result.9 In add-
ition to the impact on the patients and their friends and
family, fatigue is associated with economic costs (loss of
earning, paying for assistance). Interestingly, fatigue is
not related to the severity of liver disease10 and is unre-
sponsive to UDCA therapy,11 suggesting that the pro-
cesses responsible for fatigue in PBC are linked to the
condition but not directly to liver injury.
There have been many advances in our understanding
of fatigue over the years, starting initially with recognis-
ing it as a symptom associated with PBC, and then
appreciating the scale of the problem10 and the impact
it has on the patient’s quality of life.8 Fatigue is a subject-
ive symptom and not particular easy to study in clinical
trials, and therefore the development and validation of
the PBC-40, a disease-specific quality of life question-
naire, provides a key tool for studying fatigue in PBC.12
Studies have improved our understanding of the poten-
tial mechanisms driving fatigue in PBC and culminated
in this clinical trial of rituximab. MRI studies point to an
abnormality in muscle bioenergetic function as a poten-
tial cause of fatigue in PBC. Using the methods of phos-
phorous magnetic resonance spectroscopy (31P-MRS)
they have demonstrated excessive intramuscular acidosis
during and in the recovery from exercise. The severity
of fatigue that patients describe is associated with the
length of time that the acidosis is present and the recov-
ery time back to the baseline pH.13 As a result of these
observations, we hypothesise that the antimitochondrial
antibodies which are seen in over 90% of people with
PBC lead to over-utilisation of anaerobic pathways
through their activity against pyruvate dehydrogenase
(PDH). This is supported by MRS studies which have
shown that mitochondrial dysfunction is directly related
to antimitochondrial antibody (AMA) levels.14
Unpublished data from the Newcastle group have
demonstrated significantly lower anaerobic threshold
(AT) values compared with patients with age-matched
and sex-matched primary sclerosing cholangitis (PSC)
and sedentary controls, again supporting a muscle bio-
energetic abnormality contributing to the fatigue seen
in PBC. These findings support a trial to investigate
rituximab, an anti-CD20, B-cell depleting monoclonal
antibody as a potential treatment for fatigue in PBC.
To date there have been two pilot studies of rituximab
in PBC.15 16 Neither had fatigue as a primary outcome
measure, and instead focused on UDCA-unresponsive
disease and biochemical outcomes. Both studies found
that rituximab resulted in an improvement in liver bio-
chemistry and is safe and well tolerated in PBC. The
pilot study in Canada reported a clinically significant
reduction in fatigue but the trial was not optimised for
the study of fatigue and did not include fatigue in the
inclusion criteria, therefore potentially underestimating
the clinical effect of rituximab on fatigue.16
The RITPBC trial aims to investigate rituximab as a
treatment for fatigue in PBC. RITPBC will provide
important data on the efficacy, safety and tolerability of
rituximab in PBC, as the pilot studies have suggested
there may be a role for rituximab in treating
UDCA-unresponsive disease. The second and important
aspect of the trial will be the mechanistic data which
aims to gain a better understanding of the mechanisms
underpinning fatigue in PBC, and if a benefit is seen, to
establish the mechanism of action. The novel MRS tech-
niques used as a secondary outcome measure are
unique to this trial. Given that fatigue is not specific to
PBC, any advances in the understanding of the mechan-
isms of this symptom are likely to be transferrable to
other conditions associated with fatigue.
Research has been moving forward over the past
20 years to improve our understanding of the impact of
fatigue and identify potential mechanisms but clinical
trials of therapeutic agents have been lacking. Patients
highlight fatigue as a priority for research and close
working with the patient support groups re-iterates that
trials and subsequent treatments for fatigue are much
needed. RITPBC is the first randomised controlled trial
of a therapeutic agent to target fatigue in PBC. RITPBC
also pilots novel recruitment techniques through utilisa-
tion of the UK-PBC stratified medicine trials platform. If
this recruitment strategy proves successful it has the
potential to revolutionise trials in PBC and provide an
approach for trial recruitment transferrable to any rare
disease. This article discusses the protocol design and
methodology and will hopefully aid further trials to
target fatigue in PBC as well as being transferrable to
the many other conditions that have fatigue as a promin-
ent symptom.
METHODS/DESIGN
Study design
RITPBC is a phase II, single-centre, randomised con-
trolled, double-blinded trial comparing rituximab with
placebo in fatigued PBC patients. A total of 78 patients
(39/arm) with definite or probable PBC and moderate–
severe fatigue (PBC-40 fatigue domain score >33) will be
recruited. The primary outcome is improvement in
fatigue severity, assessed using the PBC-40, a disease-
specific quality of life measure,12 which will be evaluated
at baseline and at 12 weeks. The secondary objectives
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will be to explore the extent to which any such improve-
ment in fatigue is related to a reduction in the level of
anti-PDH antibody and to any associated effect on bio-
markers of bioenergetic function assessed using novel
MRS protocols. Other secondary outcome measures are
improvement in AT, physical activity levels, liver bio-
chemistry, daytime somnolence, autonomic symptoms,
functional status, cognitive dysfunction and anxiety and
depressive symptoms. The safety of rituximab in PBC
will be explored and the sustainability of any beneficial
actions evaluated.
Screening, recruitment and consent
Recruitment will principally be from the large clinical
cohort under follow-up at the Joint Autoimmune Liver
Disease Clinic in the Newcastle upon Tyne Hospitals
NHS Foundation Trust (>500, the largest clinical PBC
service in the UK). Participant Identification Centres
(PICs) in hospital trusts in the North of England will be
opened to aid recruitment. Articles will be written for
the patient support group LIVErNORTH and PBC
Foundation and published in their newsletters and maga-
zines. This trial is unique as it was the first trial to utilise
the UK-PBC platform for recruitment to trials. UK-PBC is
a £5 million Medical Research Council (MRC)-stratified
medicine trials platform which holds genetic, symptom
and biochemical data on over 3000 patients with PBC in
the UK. Patients recruited to UK-PBC have consented to
be contacted about trials and can therefore be easily
accessed and recruited. The UK-PBC database can be
searched for patients with a PBC-40 fatigue domain score
>33. The clinicians looking after these patients can then
be contacted and can approach the patients to see if they
would be interested in taking part in the trial. This
recruitment strategy targets patients with moderate to
severe fatigue on a national level that would be impos-
sible to do in a single-centre trial.
Potentially eligible participants are given a study
Participant Information Sheet (PIS) after which they will
have a minimum of 48 h to consider this information
before written informed consent is obtained.
Participants will have a diagnosis of definite or prob-
able PBC established using recognised epidemiological
criteria.17 18
Eligibility criteria
Inclusion criteria
Age ≥18 years
Patient has capacity and provided written informed consent for
participation in the study prior to any study-specific procedures
Moderate or severe fatigue as assessed using previously desig-
nated cut-offs of the PBC-40 fatigue domain score (ie, fatigue
domain score >33)
Presence of AMA at a titre of >1:40
Adequate haematological function haemoglobin >9 g/L, neutrophil
count >1.5×109/L, platelet count >50×109/L
Bilirubin <50 µmol
International normalised ration ≤1.5
Child-Pugh score <7
Eastern Cooperative Oncology Group (ECOG) performance status
<2
Adequate renal function; Cockcroft and Gault estimation
>40 mL/min
Women with child-bearing potential should have a negative preg-
nancy test prior to study entry and be using an adequate contra-
ceptive method which must be continued for 12 months after
completion of treatment
Exclusion criteria
History or presence of other concomitant liver diseases (including
hepatitis due to hepatitis B or C or evidence of chronic viraemia
on baseline screening), primary sclerosing cholangitis or biopsy-
proven non-alcoholic steatohepatitis
Average alcohol ingestion >21 units/week (male) or >14 units/
week (female)
Chronic sepsis or intercurrent condition likely to predispose to
chronic sepsis during the study
Previous history of aberrant response or intolerance to immuno-
logical agents
Presence of significant untreated intercurrent medical condition
itself associated with fatigue
Presence of significant risk of depressive illness (Hospital
and Anxiety and Depression Scale (HADS) score indicating
caseness)
Current statin therapy or statin therapy within 3 months of
enrolment
Ongoing participation in other clinical trials or exposure to any
investigational agent 4 weeks prior to baseline or within <5 half-
lives of the investigational drug
Major surgery within 4 weeks of study entry
Vaccination within 4 weeks of study entry; patients requiring sea-
sonal flu or travel vaccines will be required to wait a minimum of
4 weeks postvaccination to enrol in the study
Pregnant or lactating women
Psychiatric or other disorder likely to impact on informed consent
The patient is unable and/or unwilling to comply with treatment
and study instructions
Any other medical condition that, in the opinion of the investiga-
tor, would interfere with safe completion of the study
Hypersensitivity to the active substance (rituximab) or to any of
the excipients (sodium citrate, polysorbate 80, sodium chloride,
sodium hydroxide, hydrochloric acid, water (for injection)) or to
murine proteins
Active, severe infections (eg, tuberculosis, sepsis or opportunistic
infections)
Known HIV infection
Clinical history of latent tuberculosis infection unless the patient
has completed adequate antibiotic prophylaxis
Alanine transaminase (ALT)/aspartate transaminase (AST)
4× upper limit of normal
Severe immunocompromised state
Severe heart failure (New York Heart Association (NYHA) Class
IV) or severe uncontrolled cardiac disease
Malignancy (other than basal cell carcinoma) within the last
10 years
Demyelinating disease
Previous participation in this study
Any contraindication to rituximab therapy not covered by other
exclusions
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Intervention
Patients in the study will be randomised on a 1:1 ratio to
receive either:
▸ Rituximab 1 g on days 1 and 15—study drug
▸ 250 mL 0.9% sodium chloride on days 1 and 15
—placebo.
Experimental intervention: rituximab
The investigational medicinal product used in the clin-
ical trial is rituximab, 1000 mg intravenously. This
product has been approved with the European
Commission decision (MA number: EU/1/98/067/
002). Patients randomised to receive rituximab therapy
will be given treatment at the infusion rates recom-
mended for rheumatoid arthritis patients as per the
Newcastle upon Tyne Hospitals NHS Foundation Trust
protocol.
Control intervention: placebo
Patients randomised to receive placebo will receive a
control infusion of normal saline. The control infusion
will be delivered in a double blinded manner to partici-
pants using the same protocol.
Conditioning
In line with recommendations for the administration of
rituximab in other conditions, all patients will receive a
conditioning regimen prior to the infusions of study
medication on days 1 and 15 to maintain double blind-
ing. The conditioning regimen compromises paraceta-
mol 1 g orally and chlorpheniramine 4 mg orally to be
administered 1 h prior to infusion and methylpredniso-
lone 100 mg intravenously to be administered 30 min
prior to infusion.
Concomitant medications
For patients who are on UDCA, the dose will not be
changed during the period of study. No other disease-
modifying agents should be introduced during the dur-
ation of the trial. Therapy aimed at reducing pruritus
can be introduced if unavoidable at the discretion of the
investigators.
Live vaccines must not be given during the study.
Randomisation and blinding
Randomisation will be conducted by the Newcastle
Clinical Trials Unit (NCTU) web-based system on a 1:1
ratio and random-permuted blocks with random block
length. The treatment allocation will be kept blind
from the patients, study assessors and investigators
until study completion. The randomisation system will
generate a treatment number for each participant
that links to the corresponding allocated study drug
(blinded). A code-break list will be kept in the phar-
macy department.
Study procedures and outcome measures
The schedule of events which includes completion of
study questionnaires and collection of mechanistic data
is described in figure 1.
Quality of life and symptom questionnaires
The primary outcome measure is the fatigue domain of
the PBC-40. Severity of other symptoms will be assessed
in terms of numerical change for the relevant domain
of the PBC-40 (itch, cognitive symptoms, social and emo-
tional symptoms). The PROMIS HAQ (Patient-Reported
Outcomes Measurement Information System Health
Assessment, Questionnaire)19 measures the functional
and physical ability of the participants (washing, dress-
ing, arising, eating, walking, hygiene, reach, grip and
activity). The score is on a 0–100 scale with higher
scores indicating worse functional ability. Anxiety
and depression will be assessed by the HADS.20
Improvement in daytime somnolence will be assessed
using the Epworth Sleepiness Scale (ESS).21 Vasomotor
autonomic symptoms will be assessed using the
Orthostatic Grading Scale (OGS).22Cognitive function
will be assessed with the COGFAIL questionnaire.23
Fatigue diary
Participant-held diaries will be used to gather qualitative
information as to symptoms and functional ability. We
Figure 1 Schedule of events for the RITPBC trial.
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will use diaries that include both structured (quantita-
tive) and unstructured (qualitative) methods of data col-
lection. The diaries measure fatigue using a scale of 1 to
6 (1—no fatigue and 6—extreme fatigue). Participants
will be asked to complete the diaries six times during
the study. They will complete the diaries for a period of
1 week at the beginning of each month at baseline, 1, 3,
6, 9 and 12 months. They will return the diaries at the
final visit.
Muscle acidosis
Magnetic resonance data will be acquired at baseline
and at 12 weeks using a 3 T Intera Achieva scanner
(Philips, Best, the Netherlands) which is equipped
with additional specialist hardware to perform
phosphorous-31 MRS. The protocol used for acquisition
and analysis has been described elsewhere; but in
summary, it involves controlled plantar flexion using a
purpose-built exercise apparatus developed for oper-
ation within the MRI scanner.14 Participants will
perform 2×180 s bouts of plantar flexion contractions at
25% and then 35% of maximal voluntary contraction,
with each bout preceded by 60 s of rest and followed by
390 s of recovery. Phosphorous spectra will be collected
at 10 s intervals.
Anaerobic threshold
Participants will cycle on a stationary ergometer
(Corival, Lode, Nederland) between 60 and 70 rpm.
The test will be terminated voluntarily by the participant
or when they were unable to maintain a pedal frequency
of 60 rpm. Expired air will be collected at rest and
during exercise using a breathing mask and analysed
online using a gas analysis system (MetaLyzer II,
CORTEX, Germany). AT will be assessed using the com-
puterised v-slope method and values compared at base-
line and 12-week follow-up.
Physical activity levels
Physical activity will be measured objectively using two
activity monitors which will be worn for 7 days at base-
line and week 12. The first is a validated multisensor
array (SenseWear Pro3, Bodymedia Inc) which measures
four key metrics: skin temperature, galvanic skin
response, heat flux and motion via a three-axis acceler-
ometer. The sensors combined with algorithms calculate
the average daily energy expenditure relative to baseline
metabolism (metabolic equivalent: MET/day, 1
MET=resting metabolic rate), total energy expenditure
(calories per day), active energy expenditure (total cal-
ories expended over 3 MET/day), physical activity dur-
ation (min over 3METs per day) and average daily
number of steps walked. Patterns of sedentary behaviour
will be assessed by power law analyses of the lengths of
sedentary bouts fitted from raw sedentary data.
Outcome measure for study evaluation will be mean
number of steps/24 h. Second, the GENEActiv
(ActivInsights, Ltd) is a waterproof, lightweight (16 g)
triaxial accelerometer. Raw accelerations are collected at
a range of ± 8 g with a recording frequency of 40 Hz.
B-cell biology
Quantification and phenotyping of total B-cell popula-
tions and B-cell subsets will be carried out using a
FACS-based approach with a well-described protocol uti-
lising markers other than CD20.24 Outcome measure
will be a chang in individual parameters with therapy.
Total and activated B cells in peripheral blood will be
evaluated using a direct immune-fluorescence reagent
(Fast Immune CD19/CD69/CD45, BD Biosciences).
B-cell subsets will be analysed to assess naïve, memory
(CD27) and plasma cell (CD38) populations. Finally,
activation status of the B-cell populations will be ana-
lysed using CD80, CD86 and CD268.
Anti-PDH antibody total and individual isotype levels
and antibody functional inhibitory capacity will be
studied on day 0 and at the primary end point
(12 weeks after therapy). Antibody levels will also be cor-
related with long-term fatigue status during the second-
ary follow-up period to 12 months. Anti-PDH levels and
isotype patterns will be assessed using a well-established
ELISA developed within our research group.25 In the
analysis phase, impact of rituximab on fatigue in PBC
will be correlated with changes in individual autoanti-
body isotype responses and with PDH-inhibitory capacity
of serum.
Liver biochemistry
We will collect data on the reduction in serum alkaline
phosphatase level and attainment of the previously iden-
tified positive outcome measure of drop in baseline alka-
line phosphatase of >40% or normalisation (Barcelona
Criteria).26
Data analysis
Sample size calculation
A total sample size of 78 participants (39 per arm) will
be recruited and randomised; this includes an assump-
tion of 10% attrition at 12-week follow-up (based on
experience in clinical trials in PBC). The primary
outcome is the PBC-40 fatigue domain score (range
11–55) after 12 weeks of intervention. The SD of fatigue
scores is 8 units (based on the PBC-40 derivation studies
utilising >1000 patients12), with a correlation of 0.6
between baseline and follow-up time points based on
previous studies. The study is powered to detect a mean
change in PBC-40 fatigue domain score of 5 units
(equating to an average of 0.5 point change per ques-
tion; a difference in PBC-40 score demonstrated in our
population-based studies to be associated with signifi-
cantly higher levels of social function and which was,
therefore, deemed to be clinically significant for the pur-
poses of the study design) with a power of 90% and a
5% significance level. This equates to 35 participants in
each group providing data on the primary outcome
(PBC-40 fatigue score at 12 weeks): incorporating an
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assumption of a 10% attrition gives a total of 78. The
number of participants lost to follow-up, or withdrawing
consent prior to initial treatment is expected to be
minimal.
Analysis of outcome measures
Analysis will be on the basis of intention to treat.
Primary outcome
Differences between intervention and control groups at
12 weeks on PBC-40 fatigue domain scores will be ana-
lysed by analysis of covariance (ANCOVA) using baseline
scores as covariates. The time course of the comparison
between intervention and control groups over the
12-month follow-up period will be assessed using
repeated measures analysis of variance.
Secondary outcome
Secondary outcomes, covering comparison of other clin-
ical symptoms and functional capability scales at
12 weeks will also be analysed by ANCOVA using base-
line values as covariates. The time course of the com-
parison between intervention and control groups over
the 12-month follow-up period will be assessed using
repeated measures analysis of variance.
The analysis of the mechanistic variables will be more
descriptive in nature, and will involve comparison of
means or proportions between intervention groups, as
appropriate, and the use of correlation coefficients to
explore the relationship between physiological/immuno-
logical measurements and fatigue. For the secondary
outcome measures, the variables will be compared at
baseline and at 12-week assessment. Physical activity
levels will compare mean number of steps per 24 h mea-
sured over a 7-day period. AT will be measured during
cardiopulmonary exercise testing. MRS will compare the
minimum pH seen in the exercise and recovery period,
the time required postexercise for pH to return to within
0.01 units of baseline levels (calculated as the sum for
each individual of the two bouts to form a total pH recov-
ery time) and the mean ‘area under the curve’ for pH
for the 2 exercise episodes which reflects total acid
exposure. A change in the number of B cells and B-cell
subsets will be reported and also a change in anti-PDH
titres. The safety and tolerability of rituximab in PBC will
also be reported as a secondary outcome measure.
There are no planned interim analyses for efficacy;
however, if the data monitoring and ethics committee
(DMEC) requires interim analysis for safety it will be
performed. Final analyses will be carried out when all
participants have completed the follow-up.
Withdrawal of participants
Study drug must be discontinued if:
▸ The participant develops elevated serum ALT/AST
four times above the upper limit of normal;
▸ The participant decides she/he no longer wishes to
continue;
▸ Cessation of study drug is recommended by the
investigator.
Should a patient withdraw from study drug only,
efforts will be made to continue to obtain follow-up
data, with the permission of the patient.
Participants who wish to withdraw from study medica-
tion will be asked to confirm whether they are still
willing to provide the following:
▸ Study specific data at follow-up visits 5–19;
▸ End of study data as per visit 19, at the point of
withdrawal;
▸ Questionnaire data collected as per routine clinical
practice at annual follow-up visits.
If participants agree to any of the above, they will be
asked to complete a confirmation of withdrawal form to
document their decision.
Data monitoring, quality control and quality assurance
Data collection
To preserve confidentiality, all patients will be allocated
a unique study identification number, which will be used
on all data collection forms and questionnaires. Only a
limited number of members of the research team will be
able to link this identification number to identifiable
details, which will be held on a password-protected data-
base. All study documentation will be held in secure
offices and the research team will operate to a signed
code of confidentiality. A clinical data management soft-
ware package will be used for data entry and processing,
allowing a full-audit trail of any alterations made to the
data post entry. Original questionnaires, case report
forms and consent forms will be securely archived at the
Newcastle upon Tyne Hospitals NHS Foundation Trust
archive facility for 15 years following publication of the
last paper or report from the study. Data will be
handled, computerised and stored in accordance with
the Data Protection Act 1998. No participant identifiable
data will leave the study site. The quality and retention
of study data will be the responsibility of the chief inves-
tigator. All study data will be retained in accordance with
the latest Directive on GCP (2005/28/EC) and local
policy. All laboratory samples will be stored and identi-
fied using the patient’s unique study identification code.
Discontinuation rules
The study may be prematurely discontinued on the basis
of new safety information, or for other reasons given by
the DMEC and/or Trial Steering Committee (TSC),
Sponsor, regulatory authority or Research Ethics
Committee concerned.
Monitoring, quality control and quality assurance
The study will be managed through the NCTU. The
Trial Management Group (TMG) will include the chief
investigator, senior trial manager, trial manager, assistant
trial manager, data manager and other members of the
trial team when applicable. NCTU will provide
day-to-day support for the site and provide training
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through investigator meetings, site initiation visit and
routine monitoring visits. Protocol amendments will be
managed by the NCTU and communicated to the trial
team.
Data Monitoring and Ethics Committee
An independent DMEC has been appointed. It will
consist of two physicians not connected to the study and
one independent statistician and will be convened to
undertake independent review. The purpose of this com-
mittee will be to monitor efficacy and safety end points.
Only the DMEC will have access to unblinded study data.
The committee will meet a minimum of three times, at
the start, middle and completion of the study.
Trial Steering Committee
A TSC will be established to provide overall supervision
of the study. The TSC will consist of an independent
chair, two independent clinicians, independent
consumer representative, the chief investigator,
co-investigator, senior trial manager, trial manager and
trial statistician. Representatives of the trial sponsor and
funder should be invited to all TSC meetings. The com-
mittee will meet every 3 months during recruitment,
and annually thereafter for the duration of the study.
Study monitoring
Monitoring of study conduct and data collected will be
performed by a combination of central review and site
monitoring visits to ensure the study is conducted in
accordance with good clinical practice (GCP). Study site
monitoring will be undertaken by the trial manager. The
main areas of focus will include consent, serious adverse
events (SAEs), essential documents in study site files and
drug accountability and management. All monitoring
findings will be reported and followed up with the appro-
priate persons in a timely manner. The study may be
subject to inspection and audit by the Newcastle upon
Tyne Hospitals NHS Foundation Trust under their remit
as sponsor, and other regulatory bodies to ensure adher-
ence to GCP.
Recording and reporting serious adverse events or
reactions
All adverse events (AEs) should be reported. Depending
on the nature of the event, the reporting procedures
below should be followed. Any questions concerning AE
reporting should be directed to the chief investigator or
the named contact within the management team within
the NCTU in the first instance.
Adverse event (including adverse reaction)
All non-SAEs/reactions during drug treatment will be
reported on the study case report form (CRF) and sent
to the NCTU management team within 2 weeks. Severity
of AEs will be graded on a five-point scale (Mild,
Moderate, Severe, Life threatening, causing death).
Relation of the AE to the treatment should be assessed
by the investigator at site. The individual investigator at
each site will be responsible for managing all AEs/reac-
tions according to local protocols.
SAE/SAR (including SUSARs)
All SAEs, SARs and SUSARs during drug treatment shall
be reported to the chief investigator within 24 h of the
site learning of its occurrence. The initial report can be
made by secure fax which will also generate an email
copy to the chief investigator, senior trial manager and
trial manager. In the case of incomplete information at
the time of initial reporting, all appropriate information
should be provided as follow-up, on the appropriate SAE
follow-up form. As indicated above, relationship of the
SAE to the treatment (causality) should be assessed by
the investigator at the site, as should the expected
or unexpected nature (by reference to the SmPC for
rituximab) of any serious adverse reactions (SARs). The
MHRA and main REC will be notified by the chief inves-
tigator or trials management team (on behalf of the
Sponsor) of all SUSARs occurring during the study
according to the following timelines: fatal and life-
threatening within 7 days of notification and
non-life-threatening within 15 days. All investigators will
be informed of all SUSARs occurring throughout the
study on a case-by-case basis. The chief investigator will
ensure the Newcastle upon Tyne Hospitals NHS
Foundation Trust as Sponsor is notified of any SUSARs
in accordance with local trust policy.
Insurance and finance
The Newcastle upon Tyne Hospitals NHS Foundation
Trust has liability for clinical negligence that harms indi-
viduals towards whom they have a duty of care. National
Health Service (NHS) Indemnity covers NHS staff and
medical academic staff with honorary contracts conduct-
ing the study for potential liability in respect of negligent
harm arising from the conduct of the study. The
Newcastle upon Tyne Hospitals Foundation NHS Trust is
sponsor and through the sponsor, NHS indemnity is pro-
vided in respect of potential liability and negligent harm
arising from study management. Indemnity in respect of
potential liability arising from negligent harm related to
study design is provided by NHS schemes for those proto-
col authors who have substantive contracts of employ-
ment with the NHS and by Newcastle University
Insurance schemes for those protocol authors who have
substantive contract of employment with Newcastle
University. This is a non-commercial study and there are
no arrangements for non-negligent compensation.
DISSEMINATION
The data will be the property of the chief investigator
and co-investigator(s). Publication will be the responsi-
bility of the chief investigator. It is planned to publish
this study in peer-review journals and to present data at
national and international meetings. Results of the study
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will also be reported to the sponsor and funder, and will
be available on their web site. All manuscripts, abstracts
or other modes of presentation will be reviewed by the
TSC and funder prior to submission. Individuals will not
be identified from any study report. Participants will be
informed about their treatment and their contribution
to the study at the end of the study, including a lay
summary of the results.
DISCUSSION
Over recent years, there have been many advances in
gaining a better understanding of fatigue in PBC. We now
appreciate what a significant problem it is, both in terms
of the prevalence of fatigue as a symptom as well as the
impact that it can have on the patient’s lives. Although the
pathophysiology of fatigue is not entirely understood
research has enabled us to have a much better understand-
ing of the potential causes of fatigue in PBC and possible
targets for treatment. Given the recent increases in our
understanding of fatigue the next step was to design and
deliver a trial of a therapeutic agent aimed to improve
fatigue in PBC which would also improve our understand-
ing of the mechanisms of fatigue.
The trial is designed to provide useful information
about the physiological effects of fatigue, the pathophysi-
ology of fatigue as well as assessing the role of rituximab
in treating fatigue.
Fatigue is a subjective symptom and is not always an
easy symptom to study in a trial, which is why the proto-
col of this trial has been published with the hope of
aiding others who may wish to design and deliver trials
on fatigue in PBC as well as the many other conditions
that have fatigue as a key symptom. The trial also incor-
porates novel techniques that can provide objective data
on fatigue (MRS, AT and physical activity monitoring) as
well as describing new recruitment techniques using
national disease-specific databases. Forty patients have
now received either rituximab or placebo infusions as
part of the trial which make it the largest biological trial
in PBC. We believe the high number of patients
recruited to this trial is because we are addressing
fatigue which is the issue that matters most to patients.
TRIAL STATUS
Recruitment to RITPBC opened in October 2012 and
will close in April 2015.
At the time of manuscript submission the trial is open
to recruitment.
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